Benzinga's Top Pre-Market NASDAQ Losers

Vertex Pharmaceuticals Incorporated

dipped 5.91% to $50 in the pre-market session. VRTX reported interim results from the first part of a Phase 2 study designed to evaluate multiple combination regimens of VX-770 and VX-809, Vertex's lead medicines in development that aim to treat the defective protein that causes cystic fibrosis. Brigham Exploration Company

dropped 1.06% to $27 in the pre-market trading. BEXP's trailing-twelve-month ROA is 3.59%. Aixtron SE

fell 1.06% to $38.42 in the pre-market session. AIXG's PEG ratio is 7.88. Teva Pharmaceutical Industries Limited

moved down 0.20% to $49.46 in the pre-market session. TEVA's trailing-twelve-month ROA is 7.57%. Read more